Publication at First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine |
2017
Abstract
Insulin resistance and it consequences belong to major cardiovascular risk factors. Only one medicinal preparation - pioglitazone - is known to influence insulin resistance on the whole body level.
Pioglitazone was shown to reduce the cardiovascular risk of patients with diabetes mellitus in the PROactive trial that has also recorded significantly reduced risk of recurrent myocardial infarction and stroke in the pioglitazone group. The IRIS study demonstrated that the effect on insulin resistance in patients after stroke reduces the risk of reccurence of this event as well as the risk of diabetes mellitus manifestation